IBD Biomarker Panel for Pre-Treatment Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker studies for predicting response to anti-TNF therapy in inflammatory bowel disease (IBD) are limited by small sample sizes and lack of prospective validation, leading to high clinical non-responder rates and inefficiencies in treatment selection.
Innovation Solution
A panel of biomarkers, including CMTM2, C5AR1, FGF2, GK, HGF, IL1RN, LILRA2, NAMPT, PAPPA, SNCA, SOD2, STEAP4, and ZBED3, is used to predict response to anti-interleukin and JAK inhibitor treatments through gene expression analysis, allowing for personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biomarker studies are used for predicting response to anti-TNF therapy, then treatment selection can be guided, but the prediction accuracy is insufficient due to small sample sizes and lack of prospective validation
Solution Approach 1:
The patent performs gene expression analysis and biomarker panel assessment before treatment initiation to predict response. By conducting the biomarker evaluation in advance (before treatment starts), the system can identify responders and non-responders proactively, enabling personalized treatment selection and avoiding ineffective therapies.
Solution Approach 2:
The patent transitions from conventional single-biomarker or small-cohort studies to a comprehensive multi-biomarker panel approach with large prospective cohorts. This parameter expansion (number of biomarkers, sample size, validation cohorts) significantly improves prediction accuracy and clinical utility by providing more robust and generalizable results.
2Productivity
If biologic therapies such as anti-TNF agents are administered to all IBD patients, then treatment coverage is maximized, but many patients experience non-response or adverse effects
Solution Approach 1:
The system performs biomarker assessment before treatment initiation to predict which patients are likely to respond to biologic therapy. By identifying responders in advance, clinicians can selectively prescribe biologics to patients most likely to benefit, improving response rates while maintaining comprehensive treatment coverage for suitable candidates.
Solution Approach 2:
The patent establishes a feedback loop where biomarker results guide treatment decisions, and treatment outcomes can be used to refine future predictions. This feedback mechanism allows continuous improvement of prediction models and optimization of treatment selection based on actual patient responses.
3Reliability
If multiple treatment options are tried sequentially for IBD patients, then treatment efficacy may be improved, but treatment duration and patient exposure to ineffective therapies increases
Solution Approach 1:
By conducting biomarker analysis before treatment starts, the system predicts the most effective therapy in advance, eliminating the need to sequentially trial multiple treatments. This proactive identification of the correct treatment reduces treatment duration and avoids patient exposure to ineffective therapies.
Solution Approach 2:
The patent creates a predictive model that copies or mimics the complex biological response patterns to identify treat responders. This computational model allows rapid prediction of treatment response without requiring actual trial-and-error treatment, effectively replicating the outcome of multiple treatment trials through in silico analysis.
Data Source
AI summary
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.